Patients in the combined therapy group had a significant trend toward longer disease‐free survival than those in the chemotherapy alone group (3‐year disease‐free survival [DFS] of 68.79% vs. 50.81%; hazard ratio [HR] for progression or death, 0.477; p = 0.003).
← all excerpts
Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
1
—
—